NYSE:CHRO Chromocell Therapeutics (CHRO) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free CHRO Stock Alerts $1.42 -0.06 (-4.05%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.36▼$1.4850-Day Range$1.23▼$2.5952-Week Range$1.21▼$6.00Volume14,351 shsAverage Volume16,278 shsMarket Capitalization$8.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends Get Chromocell Therapeutics alerts: Email Address Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About Chromocell TherapeuticsChromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Read More CHRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHRO Stock News HeadlinesMay 20, 2024 | investorplace.comCHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024May 13, 2024 | globenewswire.comChromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024April 9, 2024 | globenewswire.comChromocell Issues Letter to Stockholders from Chief Executive OfficerMarch 21, 2024 | globenewswire.comChromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon ChandlerMarch 18, 2024 | globenewswire.comChromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023March 11, 2024 | globenewswire.comChromocell to Present at Sidoti Virtual Investor Conference March 13-14February 27, 2024 | globenewswire.comBenuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare SolutionsFebruary 21, 2024 | globenewswire.comChromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 MillionFebruary 16, 2024 | globenewswire.comChromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public OfferingSee More Headlines Receive CHRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CHRO CUSIPN/A CIK1919246 Webchromocell.com Phone732-514-2636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,770,000Free FloatN/AMarket Cap$8.19 million OptionableN/A BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Francis Knuettel II (Age 58)M.B.A., CEO, CFO, Treasurer & Secretary Comp: $107.5kDr. Eric Lang M.D. (Age 61)Chief Medical Officer Comp: $264.99kKey CompetitorsNKGen BiotechNYSE:NKGNMiNK TherapeuticsNASDAQ:INKTEstrella ImmunopharmaNASDAQ:ESLASurrozenNASDAQ:SRZNPluriNASDAQ:PLURView All CompetitorsInstitutional OwnershipAnson Funds Management LPBought 251,888 shares on 5/14/2024Ownership: 4.284%View All Institutional Transactions CHRO Stock Analysis - Frequently Asked Questions How have CHRO shares performed in 2024? Chromocell Therapeutics' stock was trading at $4.80 at the beginning of the year. Since then, CHRO stock has decreased by 70.4% and is now trading at $1.42. View the best growth stocks for 2024 here. How were Chromocell Therapeutics' earnings last quarter? Chromocell Therapeutics Co. (NYSE:CHRO) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.55) earnings per share for the quarter. When did Chromocell Therapeutics IPO? Chromocell Therapeutics (CHRO) raised $7 million in an IPO on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share. When does Chromocell Therapeutics' lock-up period expire? Chromocell Therapeutics' lock-up period expires on Wednesday, August 14th. Chromocell Therapeutics had issued 1,100,000 shares in its initial public offering on February 16th. The total size of the offering was $6,600,000 based on an initial share price of $6.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period. Who are Chromocell Therapeutics' major shareholders? Chromocell Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Anson Funds Management LP (4.28%). How do I buy shares of Chromocell Therapeutics? Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CHRO) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on...Paradigm Press | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
